LAKE OSWEGO, Ore., July 20, 2026
BIOTRONIK Neuro has unveiled Embrace One® Proactive Intelligence, a proprietary artificial intelligence (AI) capability designed to enhance the management of patients implanted with the Prospera® Spinal Cord Stimulation (SCS) System. The new technology introduces an advanced layer of AI-assisted remote monitoring that analyzes more than 200 patient-specific data points daily to identify early behavioral patterns suggesting that patients may benefit from additional clinical support or therapy optimization. Rather than making clinical decisions or automatically adjusting therapy, the AI model prioritizes patients for review by the Embrace One Care Team, a dedicated group of clinical specialists who provide personalized follow-up between office visits. Clinical findings presented at the American Society of Pain and Neuroscience (ASPN) Annual Meeting 2026 demonstrated the technology’s ability to identify patients requiring proactive intervention before they recognize therapy-related issues themselves. The innovation marks another important step toward AI-enabled personalized pain management, improving long-term outcomes while reducing unnecessary clinical visits for individuals living with chronic intractable pain.
AI Enhances Remote Monitoring for Spinal Cord Stimulation
Embrace One Proactive Intelligence builds upon BIOTRONIK Neuro’s established daily remote monitoring platform, which automatically collects objective therapy and device performance data from patients using the Prospera Spinal Cord Stimulation System. The newly introduced AI capability continuously analyzes these data streams to detect subtle behavioral and therapy-related changes that may indicate declining treatment effectiveness or emerging support needs. Importantly, the system does not replace physician judgment or independently modify stimulation settings. Instead, it provides valuable decision-support information to the Embrace One Care Team, allowing specialists to proactively contact patients, recommend therapy optimization, deliver additional education, or perform remote programming when appropriate. Because the AI operates entirely using existing device-generated information, patients and healthcare providers do not need to perform additional tasks or collect extra data, allowing seamless integration into routine clinical practice while enhancing personalized patient management.
Clinical Evidence Demonstrates Proactive Patient Support
New real-world clinical data presented during the ASPN Annual Meeting validated the effectiveness of the AI-assisted monitoring approach. In a prospective pilot study involving 175 spinal cord stimulation patients, the AI model identified 188 behavioral-pattern events that warranted review by clinical specialists. Patients responded to proactive outreach in 80.9% of identified cases, while nearly four out of five reviewed cases resulted in targeted clinical interventions, including therapy optimization, remote device reprogramming, and personalized patient education. These findings demonstrate the ability of AI to recognize subtle treatment changes before patients experience noticeable symptom deterioration, enabling earlier intervention and helping maintain stable long-term pain relief. The technology addresses one of the longstanding challenges of spinal cord stimulation therapy, where patients often delay seeking care because gradual changes in pain control may not be immediately recognized. By enabling earlier engagement, BIOTRONIK Neuro aims to improve treatment continuity while enhancing patient satisfaction and reducing unnecessary in-person clinic visits.
Advertisement
BIOTRONIK Neuro Advances AI-Driven Digital Healthcare
The launch of Embrace One Proactive Intelligence further strengthens BIOTRONIK Neuro’s leadership in combining medical devices, digital health technologies, artificial intelligence, and remote patient monitoring. As the first and only spinal cord stimulation manufacturer offering automatic daily remote monitoring, objective data transmission, and remote programming, the company continues expanding connected care solutions that improve therapy management beyond traditional clinic-based follow-up. The integration of AI into the Prospera SCS System reflects the growing role of intelligent analytics in modern neuromodulation, helping healthcare providers deliver proactive, personalized care while optimizing clinical efficiency. By leveraging continuously expanding real-world datasets generated through remote monitoring, BIOTRONIK Neuro is advancing a new standard for chronic pain management that combines AI-powered insights, remote connectivity, and expert clinical oversight. The latest innovation reinforces the company’s commitment to developing next-generation digital health technologies that improve patient outcomes while supporting the future of precision medicine and connected healthcare.
Source: BIOTRONIK press release
